<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01710605</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2011-09</org_study_id>
    <nct_id>NCT01710605</nct_id>
  </id_info>
  <brief_title>Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast Cancers</brief_title>
  <official_title>Randomized Trial to Evaluate the Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast Cancers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The STIC CTC study is a randomized trial to evaluate the medico-economic interest of taking&#xD;
      into account circulating tumor cells (CTC) to determine the kind of first line treatment for&#xD;
      metastatic, hormone-receptors positive, breast cancers. In the standard arm, the kind of&#xD;
      treatment will be decided by clinicians, taking into account the criteria usually used in&#xD;
      this setting. In the CTC arm, the type of treatment will be decided by CTC count:&#xD;
      hormone-therapy if &lt;5CTC/7.5mll (CellSearch technique) or chemotherapy if =5. The main&#xD;
      medical objective is to demonstrate the non-inferiority of the CTC-based strategy for the&#xD;
      progression-free survival: 994 patients are needed, and will be accrued in French cancer&#xD;
      centers. Secondary clinical objectives are to compare toxicity, quality of life and overall&#xD;
      survival between the two arms. The medico-economic study will compare cost per&#xD;
      progression-free life years gained of the two strategies. The financial impact of centralized&#xD;
      (one platform) vs decentralized (several platforms) CTC testing will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival evaluation</measure>
    <time_frame>2 years</time_frame>
    <description>According to RECIST 1.1 criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Economic evaluation</measure>
    <time_frame>2 years</time_frame>
    <description>Economic impact of the strategy will be evaluated (standard treatment choice vs CTC based treatment choice)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessing patient quality of life</measure>
    <time_frame>2 years</time_frame>
    <description>QLQC30 and BR23 individual questionaries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of treatment safety according to NCI-CTCAEv4.03</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluation of both chemotherapy and hormone therapy will be recorded in CRFs whatever the randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival evaluation</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">800</enrollment>
  <condition>Ductal Infiltrating Metastatic Breast Cancer</condition>
  <condition>Hormone-receptors Positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment choices (hormonotherapy or chemotherapy) are done according to standard of each center based on clinical, radiological and biological information.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Circulating Tumor Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment choices (hormonotherapy or chemotherapy) are done according to the number of CTC / 7.5 ml of blood at baseline :&#xD;
If &lt;5 CTC : Hormonotherapy If 5 or more CTC : chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Circulating tumor cells counting at baseline</intervention_name>
    <description>20 ml blood sample collected before randomization</description>
    <arm_group_label>Circulating Tumor Cells</arm_group_label>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women with metastatic ductal adenocarcinoma breast cancer&#xD;
&#xD;
          -  18 years old or more&#xD;
&#xD;
          -  Hormone receptors positive breast cancer (ER+ and/or PR+) on the last pathological&#xD;
             analysis available.&#xD;
&#xD;
          -  Acceptable patient's clinical situation compatible with chemotherapy or hormonotherapy&#xD;
             administration&#xD;
&#xD;
          -  PS &lt;4&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Evidence of measurable or evaluable disease (RECIST 1.1 criteria)in the 28 days before&#xD;
             selection&#xD;
&#xD;
          -  Information of the patient and signature of the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient treated by chemotherapy or hormonotherapy for their metastatic disease&#xD;
             (treatment failure under adjuvant hormonotherapy are accepted)&#xD;
&#xD;
          -  Her2 positive breast cancer&#xD;
&#xD;
          -  History of other stage II or III cancer in the 5 years. History of other metastatic&#xD;
             cancer (whatever the time between the two cancers).&#xD;
&#xD;
          -  Persons deprived of their freedom or under guardianship.&#xD;
&#xD;
          -  Women unable to comply with the medical follow-up of the study for geographical,&#xD;
             social or mental reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Yves Pierga</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut régional du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Azureen de Cancerologie</name>
      <address>
        <city>Mougins</city>
        <zip>06250</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital SAINT-LOUIS</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Hopital Rene Huguenin</name>
      <address>
        <city>Saint-cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de L'Ouest - Rene Gauducheau</name>
      <address>
        <city>Saint-herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>August 10, 2012</study_first_submitted>
  <study_first_submitted_qc>October 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2012</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Circulating tumor cells</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Hormone-receptors positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

